DOP2017000069A - Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores - Google Patents

Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Info

Publication number
DOP2017000069A
DOP2017000069A DO2017000069A DO2017000069A DOP2017000069A DO P2017000069 A DOP2017000069 A DO P2017000069A DO 2017000069 A DO2017000069 A DO 2017000069A DO 2017000069 A DO2017000069 A DO 2017000069A DO P2017000069 A DOP2017000069 A DO P2017000069A
Authority
DO
Dominican Republic
Prior art keywords
veliparib
carboplatin
paclitaxel
combination
lung cancer
Prior art date
Application number
DO2017000069A
Other languages
English (en)
Inventor
Giranda Vincent
Gordon Gary
d mckee Mark
Qian Jane
Qin Qin
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of DOP2017000069A publication Critical patent/DOP2017000069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para tratar el cáncer pulmonar no microcítico en un sujeto que es un fumador, que comprende administrarle al sujeto una cantidad eficaz de 2-[(2R)-2-metilpirrolidin-2-il]-1H-benzimidazol-4-carboxamida (veliparib o ABT-888), o una sal farmacéuticamente aceptable de ésta, en combinación con carboplatino y paclitaxel.
DO2017000069A 2014-09-16 2017-03-14 Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores DOP2017000069A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051040P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
DOP2017000069A true DOP2017000069A (es) 2017-05-15

Family

ID=54207780

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000069A DOP2017000069A (es) 2014-09-16 2017-03-14 Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Country Status (15)

Country Link
US (2) US9623009B2 (es)
EP (1) EP3193861A1 (es)
JP (1) JP2017527627A (es)
KR (1) KR20170055536A (es)
CN (1) CN107073015B (es)
AU (1) AU2015317856B2 (es)
CA (1) CA2959175A1 (es)
CL (1) CL2017000636A1 (es)
DO (1) DOP2017000069A (es)
IL (1) IL250708A0 (es)
MX (1) MX2017003304A (es)
PH (1) PH12017500505A1 (es)
RU (1) RU2017112960A (es)
SG (1) SG11201702129XA (es)
WO (1) WO2016044384A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110475857B (zh) * 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
US20200031920A1 (en) * 2017-04-04 2020-01-30 The George Washington University Combination Therapy for Treating Cancer
US20200129482A1 (en) * 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
EP2440203A4 (en) * 2009-06-04 2017-06-07 The Governors of the University of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase. poly(adp-ribose) polymerase and uses thereof
CN104602688A (zh) * 2012-05-15 2015-05-06 艾伯维公司 用于治疗脑转移的维利帕尼与全脑放疗的组合
JP6324381B2 (ja) * 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
US20140187537A1 (en) * 2013-01-03 2014-07-03 Emory University Methods of predicting outcomes of chemotherapy treatments and alternative therapies

Also Published As

Publication number Publication date
WO2016044384A1 (en) 2016-03-24
JP2017527627A (ja) 2017-09-21
KR20170055536A (ko) 2017-05-19
SG11201702129XA (en) 2017-04-27
AU2015317856A1 (en) 2017-03-16
CN107073015B (zh) 2020-07-21
IL250708A0 (en) 2017-04-30
CA2959175A1 (en) 2016-03-24
PH12017500505A1 (en) 2017-08-30
AU2015317856B2 (en) 2020-05-14
RU2017112960A (ru) 2018-10-17
CL2017000636A1 (es) 2017-11-03
MX2017003304A (es) 2017-08-15
EP3193861A1 (en) 2017-07-26
US9623009B2 (en) 2017-04-18
US20160074368A1 (en) 2016-03-17
US20170172985A1 (en) 2017-06-22
CN107073015A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
TW201613887A (en) Antiproliferative compounds and methods of use thereof
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
PE20180260A1 (es) Metodos y kits para tratar la depresion
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2017000050A1 (es) Terapia de combinación para el cáncer
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
DOP2017000069A (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
AR099416A1 (es) Terapia combinada para la hipertensión resistente
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor